Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Arango, C. Articles by Buchanan, R. W. Search for Related Content PubMed Citation Articles by Arango, C. Articles by Buchanan, R. W. Schizophrenia Spectrum Disorders Symptoms/Dimensions

Olanzapine Effects on Auditory Sensory Gating in Schizophrenia

OBJECTIVE: New-generation antipsychotics have been proposed to normalize the P50 sensory gating index in patients with schizophrenia. In the context of a double-blind comparison of olanzapine and haloperidol, the authors examined the effect of olanzapine on P50 suppression. METHOD: P50 measurements were obtained at baseline while patients were being treated with fluphenazine and after 12 weeks of double-blind treatment with either olanzapine (N=12) or haloperidol (N=12). RESULTS: There were no treatment group differences in P50 amplitude, latency, or sensory gating ratio. CONCLUSIONS: These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia.

This article has been cited by other articles:

				G. K. Thaker Neurophysiological Endophenotypes Across Bipolar and Schizophrenia Psychosis Schizophr Bull, July 1, 2008; 34(4): 760 - 773. [Abstract] [Full Text] [PDF]

				B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant, and N. R. Swerdlow Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures Schizophr Bull, January 1, 2007; 33(1): 69 - 94. [Abstract] [Full Text] [PDF]

				D. Potter, A. Summerfelt, J. Gold, and R. W. Buchanan Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia Schizophr Bull, October 1, 2006; 32(4): 692 - 700. [Abstract] [Full Text] [PDF]

				J. J Hagan and D. N C Jones Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia Schizophr Bull, October 1, 2005; 31(4): 830 - 853. [Abstract] [Full Text] [PDF]

				S. Louchart-de la Chapelle, I. Nkam, E. Houy, A. Belmont, J.-F. Menard, A.-C. Roussignol, O. Siwek, M. Mezerai, M. Guillermou, G. Fouldrin, et al. A Concordance Study of Three Electrophysiological Measures in Schizophrenia Am J Psychiatry, March 1, 2005; 162(3): 466 - 474. [Abstract] [Full Text] [PDF]

				L. E. Adler, A. Olincy, E. M. Cawthra, K. A. McRae, J. G. Harris, H. T. Nagamoto, M. C. Waldo, M.-H. Hall, A. Bowles, L. Woodward, et al. Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients Am J Psychiatry, October 1, 2004; 161(10): 1822 - 1828. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us